Highlights
- 1Science (New York, N.Y.) · 2025
- 2
- 3
Publications
Funding
Active
11 grants- PIR01CA316133-01Targeting Stress Hormone Receptor Signaling: Defining GR--MR Crosstalk in Triple-Negative Breast CancerNCI · 2026–2031 · via NIH RePORTER
- KPR01CA282762-02A systems-level approach to therapeutically target STING in cancerNational Cancer Institute · 2025–2030
- PIR01CA046595-39Mitogenic and Oncogenic Regulation of ERK/RSK SignalingNational Cancer Institute · 2014–2029· 4 renewals
- KPR01CA280572-04Dissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystemNational Cancer Institute · 2023–2028
- KPK99AG084860-01A1Investigating the link between propionate metabolism and agingNational Institute on Aging · 2024–2027
- PIHT9425-24-1-0299Dissecting the role of folate deficiency in lung cancer development and genomic instabilityU.S. Department of Defense · 2024–2027
- Sub-PIBCRF-24-022Targeting BRCA1-mutant breast cancer cells with folate and vitamin CBreast Cancer Research Foundation · 2024–2026 · via Dana-Farber Cancer Institute
- MPIP50CA247749-05MSK SPORE in Genomic Instability in Breast Cancer (DRP PP4: Non-Coding Mutations in Triple-Negative Breast Cancers)National Cancer Institute · 2024–2026 · via Memorial Sloan Kettering Cancer Center· 2 renewals
- MPIR03CA289863-02Targeting BRCA1/2-deficient cancers with folate and vitamin CNational Cancer Institute · 2024–2026
Completed grants (22)
- PIR03CA280299-02The role of NAGK cysteine deprotonation in nutrient stress and cancer progressionNational Cancer Institute · 2023–2025
- PICU 235791-01Folate deficiency as a source of genotoxic formaldehyde in cancerCornell University - Ithaca · 2024–2024
- Sub-PIDFCI 224656-02Targeting BRCA1-mutant breast cancer cells with folate and vitamin CBreast Cancer Research Foundation · 2022–2024 · via Dana-Farber Cancer Institute
- PIR01GM051405-29Signal Transduction to P70 S6 Kinase 1National Institute of General Medical Sciences · 2014–2024· 3 renewals
- KPK08NS128263-01Targeting cysteine susceptibility in glioblastomaNational Institute of Neurological Disorders and Stroke · 2022–2024
- PIASCO 221296-01Establishing the role of Methylmalonic Acid in KRAS-mutated Lung AdenocarcinomaConquer Cancer Foundation of the American Society of Clinical Oncology · 2022–2023
- MPIT32CA203702-01A1Molecular and Translational Oncology ResearchNational Cancer Institute · 2017–2023Training
- PIAddgene 706196Addgene 706196Addgene, Inc. · 2022–2023
- PIAddgene 705684Addgene 705684Addgene, Inc. · 2022–2023
- PIPSF 210730-01Targeting Cellular Protein Kinases As Treatment For COVID-19Pershing Square Foundation · 2020–2021
- PII11-0015Biochemical and genetic investigation of oncogenic TOR-dependent regulation of RNA metabolism and tumorigenesis using cross-species approachesStarr Cancer Consortium · 2018–2020
- KPPDF17481555The Role of Histone H3 Variants in Breast Cancer MetastasisSusan G. Komen Breast Cancer Foundation, Inc. · 2017–2020Fellowship
- KPK99CA218686-02Propionate Metabolism as an Essential Metabolic Adaptation for Tumor ProgressionNational Cancer Institute · 2017–2020Career
- PI2015082Nuclear MAPK Translocation as a Therapeutic TargetUnited States Israel Binational Science Foundation · 2016–2020
- PIW81XWH-17-1-0118Metabolic Regulation of mTORC1 Catalytic ActivityU.S. Department of Defense · 2017–2020
- PISUS 192927-01Sanofi Innovation Award (iAward)Sanofi S.A. · 2018–2019Contract
- KPF32CA217048-02Exploring the Regulation and Function of Gap Junction-Mediated Signaling in Glioblastoma MultiformeNational Cancer Institute · 2017–2019Fellowship
- PIR01HL121266-02Molecular and Biochemical Basis of LymphangioleiomyomatosisNational Heart, Lung, and Blood Institute · 2015–2018
- PIR37CA046595-26Mitogenic and Oncogenic Regulation of ERK/RSK SignalingNCI · 1988–2013 · via NIH RePORTER
- PIR21NS059428-01S1Development of a high content cell based screen for inhibitors of the mTOR signalNINDS · 2007–2009 · via NIH RePORTER
Honors & distinctions
- Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 1983
Clinical research
Active
1 study- PIFolate and DNA Damage in Patients with Lung CancerWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Available technologies
News mentions
- Prostate Cancer Hijacks Amino Acid Metabolism to Signal Hormone Therapy ResistanceAugust 20, 2026
Prostate tumors can rewire amino acid metabolism to override the normal brakes on cholesterol production, a process that may fuel hormone therapy resistance, according to a study by Weill Cornell Medicine investigators.
- Research Matters: How Folate Deficiency May Alter Genes to Promote CancerDecember 17, 2025
Dr. John Blenis's lab discovered that low levels of folate, a B vitamin essential for cell growth, can trigger specific genetic changes found in lung tumors, establishing a link between nutrition and cancer, which may open new dietary approaches for prevention and treatment.
- Dr. Nikolaos Koundouros Wins 2025 Tri-Institutional Breakout AwardJune 3, 2025
The award recognizes exceptional junior investigators for their notable research achievements, impactful findings and high potential for success as independent investigators.
- Omega-6 Fatty Acid Promotes the Growth of an Aggressive Type of Breast CancerApril 1, 2025
Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat “triple negative” breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators.
- Tumors Change Their Metabolism to Spread More EffectivelyApril 13, 2022
Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill Cornell Medicine.
Show 4 more mentions
- Aging People Accumulate a Molecule that Promotes Cancer and MetastasisAugust 19, 2020
The greatly increased risk of cancer and cancer mortality with aging may be due in part to the buildup in the body of a key cancer-promoting molecule, according to new preclinical research from scientists at Weill Cornell Medicine.
- Alterations in Chromatin Architecture Drive Cancer MetastasisNovember 26, 2019
A change in the protein composition of chromatin—the condensed, packaged form of DNA in the nucleus—boosts the expression of metastasis-related genes; blocking this change appears to stop tumor cells from forming new tumors in mice, suggests a study by Weill Cornell Medicine investigators.
- Prestigious Awards and Prizes Presented to Faculty and StudentsJuly 8, 2019
Weill Cornell Medicine faculty members honored with annual awards at Convocation and Commencement for their exemplary achievements.
- Early Career Scientist Honored with 2019 Tri-Institutional Breakout AwardJune 12, 2019
Dr. Gina Lee, a former postdoctoral fellow in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine who has now joined the institution’s faculty, has won a 2019 Tri-Institutional Breakout Award for Junior Investigators.
Media highlights
- Cornell Researchers Identify Possible New Path To Slowing Prostate Cancer Treatment ResistanceFingerLakes1.com · August 24, 2026
Mentoring
- VVVi Vien LowBiochemistry & Structural Biology · Class of 2021
- TSTanya SchildBiochemistry & Structural Biology (PhD) · Class of 2021
- DIDidem IlterPostdoc mentee · 2014–2020
- KSKripa Shobana GaneshBiochemistry & Structural Biology (PhD) · Class of 2023
- ADAna Da Silva GomesPostdoc mentee · 2014–2020
- MSMoniquetta ShaferPharmacology (PhD)
- SLShuchen LiuPostdoc mentee · 2023–2025
- CSChristie SheaTri-I Program in Chemical Biology (PhD) · Class of 2022
- ALAristotle LauBiochemistry & Structural Biology (PhD)
External relationships
Leadership Roles
Elikia INC
Ownership
Elikia INC